Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Principal Investigator
Name
Ed Partridge
Institution
University of Alabama at Birmingham
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2006-0199
Initial CDAS Request Approval
Jul 1, 2006
Title
Prediction of Ovarian Neoplasm by TVU Morphology Results and CA 125 Levels
Summary
To determine the risk of malignancy in the 1604 women found to have abnormal CA125 and/or transvaginal ultrasound
(TVU) at the initial screen and the 1566 women found to have an abnormal result at subsequent screens among the
39,115 women receiving both tests and having ovaries present in the intervention arm of the Prostate, Lung, Colorectal,
and Ovarian (PLCO) Cancer Screening Trial.
Aims

In this large trial, a positive screen was defined as CA125 > 35 U/ml; ovarian or cyst volume > 10cm3; or, solid areas,
papillary projections, or mixed components within a cystic ovarian tumor of any size. We attempted to determine further
criteria for establishing risk of malignancy in asymptomatic postmenopausal women following an abnormal screen, and
calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the
criteria.